Category: 8. Health

  • At least 55,000 people face new tests in diabetes error

    At least 55,000 people face new tests in diabetes error

    Nat WrightHealth Producer

    Getty Images Close up of hands as patient undergoes finger prick test administered by a member of hospital staff who is wearing white plastic gloves.  Getty Images

    Errors by machines used to diagnose diabetes mean at least 55,000 people in England will need further blood tests, a BBC investigation has discovered.

    Some patients have been wrongly diagnosed with type 2 diabetes and even prescribed medication they don’t need – and there could be more people affected say NHS England.

    NHSE has confirmed 16 hospital trusts use the machines, made by Trinity Biotech, which have produced inaccurate test results.

    In a statement, Trinity Biotech says it is working closely with the UK health regulator and has contacted all hospitals who use the machines.

    The BBC first reported in September 2024 that 11,000 patients faced re-testing after a machine at Luton and Dunstable Hospital issued incorrect diabetes results.

    NHS England now say type 2 diabetes diagnoses rose by 10,000 in 2024, 4% more than expected.

    The procedure, known as the haemoglobin A1C test, measures average blood sugar levels which are used to diagnose type 2 diabetes and monitor the condition.

    According to the medicines and healthcare regulator (MHRA), issues with the tests on these machines was first reported in April 2024.

    The picture is of a white woman with dark hair pulled back off her face, wearing clear frame glasses and a checked shirt with a black t-shirt underneath. She's stood in a room with books in the background and pictures on the wall.

    Vicky Davies from Kingston upon Hull has complained to her GP after being prescribed diabetes medication, then told she didn’t have the condition.

    ‘It’s had a huge effect on my life’

    Vicky Davies, 36, from Kingston upon Hull was first told she had type 2 diabetes in October 2024.

    She was advised to try and lose weight first, sent for eye screening and was later prescribed four tablets of Metformin a day – the maximum dose.

    In April 2025 she had further blood tests as part of her three month review and was told that she wasn’t diabetic, which she assumed was because she had been on Metformin.

    Later that month though, she was told her blood results might not have been accurate and advised to come off the medication immediately.

    During the four months she took metformin she suffered with stomach issues and dizziness and still feels stressed.

    “It’s had a huge effect on my life. Since the diagnosis I have suffered with stress and had to take time off work to attend appointments.

    “I’ve complained to my GP, but I didn’t really get an apology. I’m just so angry,” she told BBC News.

    In a letter from her GP, they said they were not aware of the problems occurring in the laboratories and that they work to the best of their ability with the medical information available.

    In September 2024, a message on the Bedfordshire trust website said 11,000 patients needed to be re-tested.

    It warned some of them could have been misdiagnosed with type 2 diabetes as a result of problems with tests analysed at the hospital’s laboratory.

    The trust apologised “for any emotional distress and inconvenience”.

    In July 2025, the Medicines and Healthcare products Regulatory Agency said it had received reports describing a positive bias delivered by the Trinity Biotech machines.

    This resulted in some patients being incorrectly diagnosed as pre-diabetic or diabetic.

    Side effects

    NHS trusts are already recalling patients for repeat tests and NHS England says anyone who needs a repeat test will be contacted by their GP or local hospital.

    It adds that, for people who may have been wrongly diagnosed as a result of this issue, the risk is low and they would be given lifestyle advice and offered support programmes first.

    Metformin, which may have been mistakenly prescribed for some of these patients, works by lowering blood sugar levels by improving the way the body handles insulin.

    If you experience these symptoms whilst taking diabetes medication:

    • hypoglycaemia (shaking/trembling, sweating, confusion, loss of consciousness)
    • and hyperglycaemia (excessive thirst, blurred vision, recurrent infections)

    The advice is to seek medical attention immediately.

    A woman with dark brown shoulder length curly hair and rimless glasses stands  with an open plan office in the background. She is wearing a dark purple shirt.

    Dr Clare Hambling is diabetes national clinical director for NHS England

    Dr Clare Hambling, diabetes national clinical director for NHS England, said: “Being potentially misdiagnosed with any long-term condition, such as type 2 diabetes, is understandably worrying, however the clinical risk of harm to patients following this issue is low.”

    NHS England says fewer than 10% of their laboratories were affected and all have either replaced the machines or addressed calibration issues.

    In response to an inquiry from the BBC, Trinity Biotech said: “The company has worked closely with the MHRA to resolve the issues experienced by some UK labs using the system.”

    The statement also said the company had “issued three Field Safety Notices in 2024 to all UK users, informing them of a potential positive bias issue.”

    These notices included “reiteration of details of the actions to be taken to ensure optimum operation of the system, with an emphasis on the importance of operating the system per the manufacturer’s instructions,” the statement continued.

    Continue Reading

  • This Juice May Help Lower Blood Pressure

    This Juice May Help Lower Blood Pressure

    • A new study suggests that beet juice may help lower blood pressure by altering your oral microbiome.
    • Beets are rich in nitrates, known to influence blood pressure.
    • Other foods high in nitrates include spinach, celery, fennel and kale.

    High blood pressure, also known as hypertension, is fairly common, and almost half of all adults in the U.S. have the condition. High blood pressure is defined as having a systolic blood pressure (the top number in a blood pressure reading) greater than 130 mm Hg or a diastolic blood pressure (the lower number in a blood pressure reading) greater than 80 mm Hg. 

    But just because hypertension is common doesn’t mean it’s benign. Having high blood pressure, especially when it’s not controlled, places you at a higher risk of heart disease and stroke, both leading causes of death in the U.S. and globally.

    With hypertension being so common, researchers have been looking for practical ways to help people lower their blood pressure for years now, and that includes dietary methods. Some of that research has led to beets, which contain nitrates that may help lower blood pressure. While there is mounting evidence of beets’ connection to healthier blood pressure, researchers are always digging deeper into the how and why of it. 

    Case in point: Researchers from the University of Exeter in the UK wanted to know if beet juice altered the oral microbiome, and if so, whether those changes have anything to do with changes in blood pressure. They published their findings in the journal Free Radical Biology and Medicine. Let’s break down what they found. 

    How Was This Study Conducted?

    Researchers recruited two groups of participants. An older group, consisting of 36 older adults, ages 65 to 80, and a younger group of 42 young adults, ages 18 to 30. All participants were considered healthy at baseline with normal blood pressure levels, though the older group’s blood pressures averaged higher than the younger group’s.

    There were three two-week interventions for this study. Before and after each intervention, participants went to the lab to have their mouths swabbed so researchers could look at their oral microbiomes—the good and bad bacteria that live in our mouths. They also had bloodwork and blood pressure measurements taken. Between each intervention was a two-week “washout” period to allow the oral microbiome to return to each participant’s “normal.”

    For the first intervention, participants were instructed to drink two concentrated beet juice “shots” a day, one in the morning, one in the evening, for two weeks. Each shot was 70 ml of beet juice, which is about equal to just under ⅓ cup. For the second intervention, they did the same thing, but with a placebo beet juice that had been stripped of its natural nitrates—though participants were not aware of this. The third intervention involved participants swishing with an antiseptic mouthwash twice a day. 

    What Did This Study Find?

    Researchers found that the beet juice with nitrates changed the oral microbiomes in both groups for the better, reducing harmful bacteria and increasing beneficial bacteria. But the changes in specific bacteria differed between groups. 

    The older group experienced a reduction in potentially harmful bacteria called Prevotella after drinking the nitrate-rich juice, and an increase in the growth of bacteria known to benefit health; these changes were more pronounced in the older compared to the younger group, and did not occur with the placebo juice. 

    The older adults in this study had an average blood pressure of 126/80 at baseline, which was higher than the younger group’s average baseline blood pressure, but the older group’s baseline nitrite blood concentrations did not differ from the younger group’s. Yet, while the younger group saw no significant changes in blood pressure or in blood nitrite concentration throughout the study, the older group saw an average reduction in systolic blood pressure of 7 mm Hg, plus an increase in blood nitrite concentration. This amount of reduction in systolic blood pressure is clinically significant, which means that the benefits may extend to reducing other risks, including heart disease and stroke. 

    As with any study, there is a risk of researcher error and participant bias with reporting adherence, though these participants reported 100% adherence to the study protocol. This study was also funded by the Biotechnology and Biological Sciences Research Council (BBSRC) Industrial Partnership Awards, which supports collaboration between academic research groups and industries. In this case, the collaboration might have been between the researchers and the company providing the beet juice. While this has the potential for introducing bias into the study and its results, this study does support previous research on beets and blood pressure. 

    How Does This Apply to Real Life?

    If you’re one of the 120 million U.S. adults with high blood pressure—or if you want to prevent the condition—there are several things you can do. Including beets and beet juice in your day might help. And of course, we have lots of amazing beet recipes, including our Beet Salad, Ginger-Beet Juice and Balsamic-Rosemary Melting Beets. 

    If you’re not a fan of beets, other foods high in nitrates include spinach, kale, fennel and celery. And we’ve got lots of tasty recipes that include these plants, too—like our Wild Rice, Shrimp and Fennel Soup or our Spring Green Soup with Chicken, which has both celery and spinach. 

    Here’s the thing: We don’t typically eat foods in isolation, and your whole eating pattern matters more than singling out one food. That’s why these study authors mention the Mediterranean diet, because it’s loaded with foods that naturally contain nitrates and a wealth of other essential nutrients. To get you started, we have several Mediterranean diet plans to choose from, including ones that support healthy blood pressure. Start with our 7-Day High-Protein Mediterranean Diet Meal Plan for High Blood Pressure, or if you want more, go for our 30-Day Mediterranean Diet Meal Plan for High Blood Pressure.

    Other lifestyle habits also influence blood pressure. This includes physical activity, sleep and stress. Too much sodium has been connected with high blood pressure, and so has drinking too much alcohol. Even being dehydrated may raise your blood pressure, so try to drink enough water each day. 

    Our Expert Take

    This study suggests that beet juice may help lower blood pressure, and that there may be a connection between beet juice, blood pressure and your mouth’s microbiome—including reducing potentially harmful inflammatory bacteria. Nitrates are found in many plants, including beets, spinach, kale, fennel and celery. 

    Taking a whole-health view of blood pressure means considering your diet, physical activity, stress and sleep. Choose an area you’re likely to have success with and start working on it today. While changes don’t happen overnight, small changes and healthy habits can add up to helpful benefits for your heart health.

    Continue Reading

  • Sunscreens guard against UV rays but endanger ocean health: experts | News | Eco-Business

    Sunscreens guard against UV rays but endanger ocean health: experts | News | Eco-Business

    Today’s beach outing is not the same as your grandparents’ beach outing: With intense summer heat waves now the norm due to climate change, and with the ozone layer still not fully healed, people need more and better sun protection when outdoors.

    Sunscreen offers proven protection from sunburn and skin cancer — but it’s also often comprised of a cocktail of ingredients including chemicals that scientists warn are a growing source of environmental pollution.

    Much of this concern focuses on a variety of ingredients known as ultraviolet (UV) filters. Sunscreens typically come in two forms: organic (using chemicals to absorb solar radiation), or inorganic (using zinc oxide and titanium oxide to reflect away solar radiation).

    An estimated 6,000 to 14,000 metric tons of UV filtering chemicals are released annually into coastal regions with coral reefs. And in recent years, scientific evidence of sunscreen chemicals harming sensitive marine ecosystems has accumulated, resulting in a series of local, regional and national bans of some chemical ingredients to protect living reefs.

    Experts now underline that these concerns go far beyond coral reefs.

    In a 2025 paper, researchers at Plymouth Marine Laboratory in the UK outlined how some sunscreen chemicals impact a host of marine organisms at a molecular, cellular, individual or community level. Studies show that UV filters are linked to effects on enzyme growth, endocrine disruption, reproductive issues and more. UV filters can affect not only coral, but species of seagrass, fish and other marine life.

    There are multiple axes of toxicities associated with the petrochemical sunscreens, ranging from reproductive development toxicities to neurotoxicity to increased risk for mutagenicity and carcinogenicity and then endocrine disruption.

    Craig Downs, executive director, Haereticus Environmental Laboratory

    The researchers are calling for an “urgent investigation” of the wider impacts on marine life. “If there’s a risk that these chemicals can harm coral and other marine life, if there’s less harmful compounds out there that we can use instead, then we need to establish what they are,” says Anneliese Hodge, a Ph.D. student at Plymouth Marine Laboratory and lead author of the 2025 paper. “We need to research that … and figure out the alternatives.”

    Experts emphasise that sunscreen ingredients number among the many thousands of other synthetic pollutants that leak into the environment annually, most of which haven’t been tested for safety. Scientists have already assessed that humanity has crossed a “safe operating space” for chemical pollution and release of these “novel entities.”

    In addition, there are preliminary findings that some chemicals used in some sunscreens may also impact human health — though those findings are still cloaked in uncertainty due to a lack of long-term ecotoxicological testing. These early findings have given rise to an “anti-sunscreen” movement in the media that experts say must be addressed with caution to avoid misinformation.

    Sunscreen’s environmental toll

    UV filters are known as a “pseudo-persistent pollutant.” Over time, they will degrade, though some may break down into more toxic forms. However, the speed of degradation is being outpaced by the rapid and consistent rate at which they’re flowing into the environment.

    Sunscreen chemicals wash off beachgoers’ or sunbathers’ bodies or enter the environment via wastewater. Many treatment facilities can’t remove them, meaning that potentially vast quantities of wastewater effluent contain UV filters. This pollution load reaches environmentally concerning levels during the Northern Hemisphere’s peak summer holiday season.

    It’s not only sunscreens that are responsible; UV filters are present in an array of cosmetics and also released by various industries, says Lenka McGachy, professor of environmental chemistry at the University of Chemistry and Technology, Prague.

    This ubiquity makes them a common pollutant in waters across the world, even in far-flung locales like Antarctica.

    Numerous studies have outlined the ways in which corals, seagrass, fish and other marine organisms are susceptible to sunscreen chemical ingredients. Studies show they can prompt coral bleaching, impact zooplankton hatching or development rates, and cause impairments to the structure of sea urchin sperm. Other research has found UV filters in species like rainbow trout, threatened loggerhead turtles and dolphins.

    But knowledge gaps remain, say experts. A 2025 paper notes “significant or complete data gaps for acute and chronic exposure data” of organic UV filters for freshwater “amphibians, sediment organisms, aquatic fungi and other rarely tested organisms.”

    Craig Downs, an ecotoxicologist and executive director of the Haereticus Environmental Laboratory in the US, emphasises that these contaminants are found not only in coastal waters but also in freshwater lakes and streams. “There are multiple axes of toxicities associated with the petrochemical sunscreens,” he says. “Ranging from reproductive development toxicities to neurotoxicity to increased risk for mutagenicity and carcinogenicity and then endocrine disruption.”

    A troubling, largely unanalyzed brew

    Sunscreen pollution poses a big problem for researchers: It isn’t happening in a vacuum. It exists in the environment alongside a host of other contaminants, and how they all interact remains unknown. “When you have a complex mixture of chemicals, like what you might have at a wastewater effluent site, it can potentially increase the overall impact on the organism,” Hodge says. Sorting out interaction impacts is challenging.

    For example, one troublingly recent study found that sunscreen chemicals, including ethylhexyl methoxycinnamate (EHMC), can bind to plastics in the environment and slow their degradation.

    “It’s as if [EHMC] acts like a ‘biofilm stabiliser,’ shielding the plastic and its microbial inhabitants from natural degradation processes,” study co-author Sabine Matallana-Surget, a professor of environmental molecular microbiology at the University of Stirling, UK, wrote in an email. “Plastic already takes up to a century to degrade in the ocean; if it’s covered by stabilising biofilms triggered by co-pollutants like EHMC, its persistence could be even longer.”

    Equally worrying is that this comingling can create a “co-pollution scenario” with the microbial communities that cling to plastic-UV filter surfaces, posing a risk to marine ecosystems and human health. If marine organisms ingest these plastics, they not only face harm from the physical plastic, but also from the chemicals coated and absorbed by it.

    There’s still another concern, says Awadhesh Jha, a professor of genetic toxicology and ecotoxicology at University of Plymouth: The bioaccumulation of UV filters and other chemicals in marine species may end up being consumed by people.

    An estimated “4.3 billion people are reliant on fish for 15 per cent of their protein intake,” he says. “Safeguarding production of healthy seafood in the changing environment is crucial for the sustainability of aquaculture industries.”

    Coral- and reef-safe, or not?

    Experts are urging stricter regulation of sunscreen marketing, noting that while some readily available sunscreens branded as “reef-safe” or “coral-safe” don’t contain chemical UV filters, these brands often don’t come with actual evidence of meeting safety goals.

    These labels, in some instances, amount to little more than greenwashing, according to experts. Studies suggest that a number of sunscreens branded reef- or coral-safe are “a bit less toxic than the not environmentally friendly sunscreens,” but are still toxic, says Pedro Echeveste De Miguel, a marine microbial ecologist at the University of the Balearic Islands, Spain.

    For many products, these claims are made without adequate toxicity testing or proof to validate them. “That’s really concerning. It misleads consumers into thinking that they’re doing the right thing,” Hodge says.

    There’s also a need to challenge assumptions and claims that inorganic mineral-based sunscreens are always better for the environment than formulas using organic UV filters. A recent paper found that “coral-friendly” sunscreens containing zinc oxide (a mineral formulation) caused severe impacts to soft and hard corals, as compared to “reef-safe” formulas containing organic UV filters that caused mild or no effects.

    “This shows why credible, standardised testing is urgently needed,” says Johanna Leonhardt, director of operations at Soneva Conservation & Sustainability in the Maldives, who was part of the study. She also emphasises that ecotoxicology testing must not only include individual ingredients, but also full formulation testing, and that companies should fully disclose active filter ingredients.

    A sensitive topic

    While sunscreens can have real environmental impacts, misinformation is also rife. Social media has recently given rise to an avid anti-sunscreen movement spreading unsubstantiated claims that these products cause a range of diseases, including cancer.

    That being said, there are concerns among experts regarding studies finding that chemicals used in sunscreens (such as avobenzone, oxybenzone, octocrylene and ecamsule), when applied to the skin, can enter the bloodstream. Similarly, research suggests inorganic sunscreens containing nanoparticles can get into the blood. But still other studies suggest these chemicals may have no impact and are safe, though more research is needed.

    A major health concern for both people and marine life is the potential for endocrine disruption linked to some chemicals. As with the environmental concerns, much of the human health focus has coalesced around two ingredients: oxybenzone and octinoxate.

    “This isn’t just about damaging coral. These compounds have the potential to damage health, to cause problems with human health,” says Greg Kearns, associate dean for research at Texas Christian University’s Burnett School of Medicine in the US

    “No studies been done to say this amount of this sunscreen and this chemical causes this injury or illness,” Kearns cautions. “But we know the potential exists. And if the potential exists, that begs the question in science, do we need to know more about this? I think the answer is, yes.”

    Studies suggest that a range of chemicals — including oxybenzone, ethylhexyl methoxycinnamate (octinoxate) and 4-methylbenzylidene camphor — should be avoided during pregnancy due to their endocrine-disrupting potential. Research published last year found that sunscreen ingredients like phenols and parabens could also increase the risk of hypertension during pregnancy.

    In 2021, the US Food and Drug Administration assessed that only zinc oxide and titanium oxide are “generally recognised as safe and effective,” noting that 12 other ingredients didn’t meet FDA criteria due to lack of data. Elsewhere, the EU has placed limits on the use of oxybenzone and homosolate. Recently, the Australian government flagged the same chemicals for restrictions due to health concerns.

    All these data put users worried about environmental and potential health effects in a tricky spot, especially given that specific ingredients and concentrations are often not listed on product bottles or squeeze tubes.

    David Andrews, acting chief science officer at the Environmental Working Group, a research and advocacy nonprofit, says that ultimately it’s not “an all-or-nothing type equation” for sunscreen users. “We know getting sunburned is bad and sunscreen is one of those tools against that,” he says.

    His organisation suggests using mineral-based sunscreens first as the safest option — both from a health and environmental perspective — but also stresses that, ultimately, decisions on use should be based on what works best for each person.

    Others such as Hodge agree that although several studies suggest mineral UV filters may be less acutely harmful than some organic filters, but uncertainties about particle behaviour and sub-lethal effects mean further research is required.

    “Sometimes the narrative when we discuss sunscreens and its impact on marine life, it quickly … steers towards people thinking that we’re telling them that they can’t wear sunscreen, and that they think it needs to be a choice between harming marine life or getting skin cancer,” she says. “I think it’s important that consumers do know that we’re not telling them to not wear sunscreen.”

    Screening your sunscreen

    Experts Mongabay spoke to agree that changes are needed in the way sunscreens are made and regulated to better protect people and Earth. Industry and manufacturers also must do much more to ensure and prove the safety of their products.

    “We support much needed efforts to do a more comprehensive review of health and environmental concerns,” Andrews says. “That includes substantiating the safety and toxicity of these sunscreens during long-term usage.”

    He underlines that this is not a call for people to abandon sunscreen use, but for consumers to educate themselves and scrutinise ingredients, and make use of traditional techniques to manage exposure to the sun. “You don’t want to overly rely on sunscreen,” he notes, stating that appropriate clothing, sun hats and seeking shade are important in sun protection.

    Downs, from the Haereticus lab, says more urgent innovation is needed to formulate safe sunscreen. “If you want to make sunscreen safe, then you need an active ingredient that can be [used] at high doses, doesn’t absorb systemically into the skin and doesn’t cause toxicity,” he says. “Some of the mineral sunscreens, if they’re made correctly, could meet that demand.”

    Others emphasise the use of “green chemistry” principles to ensure ingredients don’t persist or cause harm. New formulations, some using natural ingredients, hold promise.

    But in Downs’ view, real change won’t happen without prompting from governments and regulatory bodies. “If you were to say in four years or five years, we’re going to ban petrochemical sunscreen chemicals, like they’ve done in Palau [a Western Pacific island nation], you would get a serious investment and activity in true green chemistry innovation to find a hopefully toxicologically safer ingredient and one that doesn’t persist in the environment.”

    An industry move is currently underway to add sun protection factor (SPF) boosters to products to reduce the volume of UV filters used. While this would cut the UV filter pollution load, shifting from one chemical to another without testing for impacts is potentially problematic. “We don’t really know the full extent that some of these compounds can also have on the marine environment,” Hodge says.

    “We really need more evidence and more research to fully know exactly what we need to be switching to,” she says. “And we need to find that healthy balance between providing sufficient sun protection whilst also ensuring that our sunscreen ingredients are environmentally conscious.”

    This story was published with permission from Mongabay.com.

    Continue Reading

  • The Doctor Fighting Medicine’s Addiction to Plastic Waste

    The Doctor Fighting Medicine’s Addiction to Plastic Waste

    Just steps from the operating theaters at Melbourne’s Footscray Hospital, a storeroom holds a quiet rebellion against medical waste. Stacked neatly on wire racks are bundles of surgical gowns and drapes — some wrapped in pale blue disposable plastic, others in washable fabric that’s made to last.

    The difference seems small, but to critical-care doctor and anesthesiologist Forbes McGain, the latter pile signals a hospital daring to push back against the tide of single-use items pervasive in healthcare.

    Continue Reading

  • Nighttime rituals help shield memory from Alzheimer’s damage

    Nighttime rituals help shield memory from Alzheimer’s damage

    A full night of deep sleep is not a luxury – it might be a shield. New research suggests that the right kind of sleep can help ward off memory trouble in people whose brains already show signs of Alzheimer’s disease.

    Scientists studied older adults with no diagnosed dementia and found something striking. When these adults spent more time in the deepest stage of sleep, their memory held up better even if amyloid deposits were present.

    Understanding amyloid plaque


    Linked with Alzheimer’s disease, amyloid plaques are clumps of protein fragments, called amyloid-beta, that build up between nerve cells in the brain.

    Normally, your body produces and clears these protein fragments without a problem. But in Alzheimer’s, the cleanup process doesn’t keep up.

    The fragments start sticking together, first in small clusters that may be toxic, and eventually in larger, sticky deposits known as plaques.

    These plaques interfere with how neurons communicate, almost like static on a phone line, and they can also trigger the brain’s immune cells to overreact, causing damaging inflammation.

    Scientists study amyloid because it seems to play a central role in the chain of events that leads to memory loss and cognitive decline.

    But here’s the tricky part: we still don’t know if amyloid plaques are the main cause of the disease or more like a byproduct of deeper problems

    Sleep, brain waves, and Alzheimer’s

    The study tracked 62 cognitively healthy older adults and measured sleep and memory on the same timeline.

    Researchers used positron emission tomography (PET) to measure amyloid in the brain and monitored sleep with electroencephalography to capture brain waves overnight.

    Deep sleep here means NREM slow-wave sleep, a stage marked by large, slow oscillations that help the brain reset. The team then gave participants a face-name memory task the next day and compared performance.

    This work comes from Matthew Walker and colleagues at the University of California, Berkeley. The project also examined whether sleep helped beyond other known cognitive reserve factors like education and physical activity.

    Deep sleep resets the brain

    Deep sleep helps the brain tune synapses and prepare for new learning the next day. It also supports the transfer of fragile short-term memories into more stable long-term storage.

    There is another piece that matters for Alzheimer’s biology.

    During sleep, the brain’s glymphatic system ramps up clearance of waste proteins, including amyloid and tau, by moving cerebrospinal fluid through tiny channels that flush neural tissue.

    Findings from older adult brains

    Among people with similarly high amyloid levels, more deep sleep lined up with stronger next-day memory.

    That link was specific to the deep, slow-wave part of non-rapid-eye-movement (NREM) sleep, not lighter sleep or REM.

    “Think of deep sleep almost like a life raft that keeps memory afloat, rather than memory being dragged down by the weight of Alzheimer’s disease pathology,” said Walker.

    The benefit appeared where it was needed most – in those carrying a higher amyloid burden. It also remained even after accounting for age, sex, body mass index, gray matter atrophy, education, and physical activity.

    Poor sleep, higher Alzheimer’s risk

    Short sleep in older adults is linked to more amyloid and lower cognitive scores.

    A large analysis of more than 4,000 adults found a higher amyloid burden among those reporting six hours or fewer per night, along with worse memory.

    Researchers see a two-way pattern. Poor sleep can go hand in hand with rising amyloid, and rising amyloid can disrupt sleep quality.

    These feedback loops make sleep a practical target. It is a daily behavior with clear, measurable features and plenty of room for improvement.

    Pills don’t replace deep sleep

    Not all sleep is equal, and some sedatives change the structure of sleep in unhelpful ways.

    A 2023 review reported that benzodiazepines tend to reduce the time spent in the deepest NREM stages while expanding lighter stage 2 sleep.

    There is also interest in a newer class of sleep medicines that act on the orexin system.

    In a small randomized trial, the insomnia drug suvorexant reduced cerebrospinal fluid levels of amyloid beta and phosphorylated tau over several hours in healthy middle-aged adults.

    These findings do not mean a pill will protect memory or that anyone should change treatment without medical guidance. However, they do suggest that the type and depth of sleep matter at least as much as the number of hours.

    Better sleep, lower Alzheimer’s risk

    Simple habits can tilt sleep toward deeper stages. Avoiding caffeine – especially later in the day – helps the brain reach consolidated slow-wave sleep.

    Regular movement, a cool and dark bedroom, fewer screens at night, and even a warm shower an hour before bed can all make it easier to fall asleep.

    Scientists still need long-term studies to determine whether training deep sleep over months or years can slow cognitive decline in people with rising amyloid.

    Teams are also exploring safe ways to amplify slow waves during sleep, using sound cues or gentle electrical stimulation.

    The ultimate goal is simple: help the brain keep learning day after day, even in the face of early disease markers.

    The study is published in BMC Medicine.

    —–

    Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates. 

    Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

    —–

    Continue Reading

  • Hypertensive Kidney Disease Death Rate Up 48% in Past 25 Years

    Hypertensive Kidney Disease Death Rate Up 48% in Past 25 Years

    Joiven Nyongbella, MD

    Credit: Joiven Nyongbella on LinkedIn

    The death rate from hypertensive kidney disease in the US has increased by 48% since 1999, according to findings from a recent analysis of US Centers for Disease Control and Prevention – Wide-Ranging Online Data for Epidemiology Research (CDC WONDER) data.1

    In addition to the stark increase in high blood pressure-related renal disease mortality over the past 25 years, study findings highlight disproportionate impacts on African American and Hispanic males, underscoring the need for equitable interventions and efforts to address structural barriers in order to reduce disparities and improve outcomes.1

    “This is the first study to examine 25 years of national data on hypertensive kidney disease deaths across all U.S. states and major demographic groups,” Joiven Nyongbella, MD, an internal medicine resident at Wayne State University/Henry Ford Rochester Hospital, said in a statement.2 “Despite national efforts to reduce health inequalities, Black individuals still had over three times the death rate compared to other groups of people.”

    Hypertension is a major risk factor for end-organ damage, including kidney damage. According to the National Kidney Foundation, it is the second leading cause of end-stage renal disease after diabetes and contributes significantly to both morbidity and mortality.3

    “High blood pressure isn’t just about strokes or heart attacks – it’s also a major cause of kidney disease and death, especially in Black and Hispanic communities,” said Nyongbella.2 “The message is simple: check your blood pressure, treat it early and don’t ignore it, because it can quietly lead to life-threatening kidney problems.”

    To better understand mortality trends and disparities in hypertensive renal disease, he and a team of investigators analyzed death data from the CDC WONDER database from 1999 to 2023 using ICD-10 codes for hypertensive renal disease with and without renal failure. Age-adjusted mortality rates (AAMRs) per 100,000 were calculated and stratified by year, sex, race, ethnicity, and region.1

    Results showed that from 1999 to 2023, hypertensive renal disease caused 274,667 deaths among individuals ≥ 15 years of age, with AAMR increasing from 3.3 to 4.91 (average annual percent change [AAPC], 1.51%; 95% CI, 0.53–2.50; P = .0023).1

    Upon analysis, men had a greater mean AAMR than women (4.48 vs 3.69; P <.001), with a 22% increased mortality in cases with renal failure (P <.0001) but no significant sex differences observed in cases without renal failure (P = .36).1

    Investigators called attention to significant differences across racial groups, with Black individuals having the highest mean AAMR (10.37) versus 3.33-3.90 in other groups. Of note, this disparity remained consistent regardless of renal failure status. Additionally, Hispanic individuals had a 15% higher AAMR when compared to non-Hispanic individuals (4.55 vs 3.97; P <.001).1

    Regionally, the West had the greatest overall AAMR (4.59), but the 3 states with the highest rates were in the South: Washington DC (7.6), Tennessee (5.9), and Mississippi (5.83).1

    “This study provides important observational data indicating a concerning rise (48%) in age-adjusted deaths due to high blood pressure-related kidney disease over the last 25 years, especially among men, and Black and Hispanic individuals,” said Sidney Smith Jr, MD, a cardiologist and professor of medicine at the University of North Carolina’s School of Medicine.2 “These findings are in line with the recently released 2025 AHA/ACC High Blood Pressure Guideline and AHA’s Presidential Advisory on Cardiovascular Kidney Metabolic (CKM) Health. Both papers emphasize the importance of early treatment for high blood pressure, its direct link to kidney disease, as well as the impact of social factors among high-risk populations.”

    References

    1. Nyongbella J, Pineiro De Jesus P, Lavu V, et al. Hypertensive Renal Disease Mortality in the United States (1999–2023): A 25- Year Analysis of Trends and Sociodemographic Disparities. Hypertension.
    2. American Heart Association. Deaths from high blood pressure-related kidney disease up nearly 50% in the past 25 years. EurekAlert! September 4, 2025. Accessed September 4, 2025. https://www.eurekalert.org/news-releases/1096246?
    3. National Kidney Foundation. High Blood Pressure and Chronic Kidney Disease. Accessed September 4, 2025. https://www.kidney.org/high-blood-pressure-and-chronic-kidney-disease

    Continue Reading

  • Beta-Blockers Don’t Benefit All Heart Attack Survivors — and May Raise Heart Risks for Women

    Beta-Blockers Don’t Benefit All Heart Attack Survivors — and May Raise Heart Risks for Women

    New research has found that beta-blockers — medications commonly prescribed to lower heart rate and blood pressure — did not offer clear benefits for certain heart attack patients.

    The study, known as the REBOOT trial, included more than 8,500 people in Spain and Italy who were recovering from a heart attack. All participants had mildly-reduced heart function, but not heart failure.

    Participants were assigned to either take a beta-blocker or not, within two weeks of leaving the hospital. Researchers found that over the course of almost four years, there was not a significant difference in all-cause death rates, repeat heart attacks, or heart failure hospitalizations between the two groups — suggesting that beta-blockers didn’t offer a notable benefit when taken following a heart attack.

    Lead study author Borja Ibáñez, MD, PhD, says that while the results weren’t necessarily surprising — the clear lack of benefit was.

    Continue Reading

  • CAGE Bio Reports Strong Results from its Phase 2b Atopic Dermatitis Trial

    CAGE Bio Reports Strong Results from its Phase 2b Atopic Dermatitis Trial

    • The investigational topical drug CGB-500 outperformed efficacy benchmarks while meeting safety endpoints
    • 59% of patients achieved IGA treatment success
    • 71% of patients experienced ≥4-point improvement in worst itch

    SAN CARLOS, Calif., Sept. 4, 2025 /PRNewswire/ — CAGE Bio, a biotechnology company advancing ionic liquid–based therapies for immune-mediated skin diseases, today announced positive topline results from its double-blinded, Phase 2b dose-ranging trial of CGB-500 in patients with atopic dermatitis (AD). Globally, AD affects over 200 million people of which ~92% have <10% affected body surface area1, of which ~40% suffer from moderate to severe disease. In the US alone, 6.6 million people suffer from moderate to severe atopic dermatitis2 and an overwhelming number of these have <10% affected body surface area (BSA) with limited effective treatment options. 

    The Phase 2b study enrolled 180 patients ≥12 years of age at 16 sites across the United States. A large majority of patients (~85%) had moderate AD, while 9% had mild and 6% had severe AD, all with affected body surface area <10%.

    The trial met primary and secondary endpoints, demonstrating best-in-class treatment success, rapid itch reduction, and a favorable safety profile.

    • 59% of patients achieved Investigator’s Global Assessment (IGA) treatment success (Clear or Almost Clear with ≥2-grade improvement)—higher than reported by other topical therapies in AD.
    • 71% of patients experienced ≥4-point improvement in worst itch (PP-NRS)
    • 35% achieved complete itch resolution (“0” itch score).

    Efficacy results were statistically significant vs. vehicle, setting a new benchmark for treatment success for topical therapies in AD.

    This is a highly significant advancement. There are limited topical options for patients with moderate-to-severe atopic dermatitis (AD) with low body surface area involvement, and physicians often prescribe systemic medications. CGB-500 may offer a much-needed alternative for localized skin-directed treatment for these patients. The rapid and sustained itch relief reported by patients and high rate of disease improvement as adjudicated by the study dermatologists makes this an attractive proposition” said Justin Ko, MD MBA, Board-Certified Dermatologist and Scientific Advisory Board chair for CAGE Bio.

    CGB-500 was well tolerated with no new or unexpected safety signals, underscoring its potential as a safe and effective option for long-term management of AD.

    “Ionic liquid technology enables local delivery of medicine at efficacy levels comparable to systemic drugs, but with a safety profile similar to topicals. It is exciting to see this technological advantage translated into benefit for patients,” said Dr. Samir Mitragotri, inventor of the ionic liquid platform.

    “These results mark an important milestone for CAGE Bio and, most importantly, for patients living with this burdensome disease. These data further strengthen our belief in our mission to provide high efficacy targeted and localized treatment of immunological skin diseases. We are excited to rapidly advance CGB-500 into Phase 3 trials and towards potential registration,” said Dr. Nitin Joshi, CEO of CAGE Bio.

    CAGE Bio looks forward to sharing the full data at an upcoming scientific congress. 

    About CAGE Bio

    CAGE Bio Inc. is a biotechnology company dedicated to developing innovative therapies for immune-mediated diseases using its proprietary ionic liquid technology platform. The company’s pipeline includes clinical and preclinical assets targeting high-incidence dermatological conditions.

    1Silverberg, J. I., et al., https://doi.org/10.1089/derm.2022.29015.jsi

    2https://allergyasthmanetwork.org/what-is-eczema/eczema-statistics/

    SOURCE CAGE Bio Inc.

    Continue Reading

  • Gene that human ancestors lost millions of years ago could help treat gout

    Gene that human ancestors lost millions of years ago could help treat gout

    Millions of years ago, humans’ ancestors lost the function of a specific gene — but switching that gene back on could help protect people from gout, a new experimental study suggests.

    Gout is a type of arthritis that causes sudden, severe pain and swelling in the joints. It happens when there is too much uric acid in the blood, which can form sharp crystals in the joints, triggering painful inflammation. The painful attacks can come on quickly and may last for days or weeks.

    Continue Reading

  • Cat euthanized after eating H5N1-contaminated RAWR raw food

    Cat euthanized after eating H5N1-contaminated RAWR raw food

    The Food and Drug Administration (FDA) has confirmed H5N1 highly pathogenic avian influenza (HPAI) contamination in specific lots of RAWR Raw Cat Food Chicken Eats following the death of a cat that consumed the product. Whole genome sequencing indicates the virus strains detected in the animal and the contaminated pet food originated from a common source.

    The San Francisco Department of Public Health notified federal authorities after a cat became ill with H5N1 and was subsequently euthanized. The animal had consumed product from Lot CCS 25 093 with a sell-by date of October 3, 2026. Initial PCR testing of the open product sample collected from the pet owner detected H5N1, which was later confirmed through additional testing by USDA National Veterinary Services Laboratories.

    FDA collected and tested two retail samples of the same product from a different lot (CCS 25 077, sell-by date September 18, 2026). Both samples tested positive for Influenza A Virus, with one sample confirmed positive for H5N1 through whole genome sequencing.

    The contaminated products are sold frozen in 2.5-pound resealable plastic bags containing 40 one-ounce sliders. The yellow and white bags with black lettering are distributed in retail stores nationwide and online. Lot CCS 25 077 is printed on the center back of affected bags.

    “FDA is concerned about the lots of RAWR Raw Cat Food Chicken Eats described above because whole genome sequencing suggests the H5N1 detected in the now-deceased cat and in Lots CCS 25 093 and CCS 25 077 of the Chicken Eats product originated from a common source of contamination,” the agency stated in its release.

    Laboratory analysis identified the virus as genotype B3.13, which has previously been found in other raw poultry-based pet food brands associated with feline illness or death. The sequencing results showed H5N1 from all three samples were within the same cluster, indicating relatedness to a virus lineage detected from November to December 2024 that is no longer circulating.

    H5N1 can cause illness and death in birds, poultry and mammals including domestic cats and large felids such as panthers, bobcats and mountain lions. While dogs can contract the virus, they typically exhibit mild clinical signs and lower mortality rates compared to cats. No cases have been detected in dogs within the U.S., though fatal cases have occurred in other countries.

    The FDA reports no known human cases of HPAI contracted through exposure to contaminated pet food. The agency continues its investigation and will provide updates as new information becomes available.

    Continue Reading